T-Cell engager
Candid Therapeutics Launches with $370 Million Funding, Aims to Revolutionize T Cell Engager Market for Autoimmune Diseases
Candid Therapeutics, T Cell Engager, Autoimmune Diseases, Biotech Funding, Ken Song, Pharmaceutical Industry
Gilead Sciences Strikes Deal with Merus for Trispecific Antibody Development
Gilead Sciences, Merus NV, Trispecific antibodies, T-Cell engager collaboration, Cancer therapy innovation